ALSO NOTED: Advanced Magnetics announces positive data; Novartis sells Gerber for $5.5B; and much more...

> Shares of Advanced Magnetics were on the rise after researchers announced positive data from two additional late-stage studies of Ferumoxytol as an intravenous iron replacement therapeutic. Release

> Novartis has sold baby-food maker Gerber's for $5.5 billion. The Swiss drug company says that the sale will allow the company to focus more on its pharmaceutical business. Release

> Russian drug maker Pharmstandard says it will float up to 40 percent of its shares on exchanges in Moscow and London later this year. Report

> Xoma plans to begin clinical testing of Xoma 052 for Type 2 diabetes after reporting positive new data on the therapy. Release

> Cell Therapeutics is offering $37.2 million in shares. Release

And Finally… A "carbon audit" finds that clinical trials produce large amounts of greenhouse gases alongside the data. Report

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.